| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Manabu Takano, Tsuyoshi Okada, Katsutoshi Shioda, Chikara Yonekawa, Shiro Sud. Risperidone suppresses caffeine-induced hyperthermia and hyperactivity in rats. Neuroscience letters. 2024-09-02. PMID:39222834. |
in vivo microdialysis was used to determine the effect of risperidone on caffeine-induced elevation of dopamine (da), serotonin (5-ht), and noradrenaline (na) concentrations in the anterior hypothalamus. |
2024-09-02 |
2024-09-05 |
rat |
| Mark E Bardgett, Molly S Griffith, Kathleen R Robinson, Rachel M Stevens, Matthew A Gannon, Meghan D Knuth, Gregory S Hawk, James R Paul. Early-life risperidone alters locomotor responses to apomorphine and quinpirole in adulthood. Behavioural brain research. 2024-08-02. PMID:39094954. |
using rats as a model, we examined the effects of early-life risperidone, the most prescribed antipsychotic drug in children, on locomotor responses to the dopamine d |
2024-08-02 |
2024-08-06 |
rat |
| Hideo Kato, Chihiro Shiraishi, Mao Hagihara, Hiroshige Mikamo, Takuya Iwamot. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database. Scientific reports. vol 14. issue 1. 2024-05-31. PMID:38822123. |
the frequency of visual hallucinations with voriconazole alone and in combination with a dopaminergic medicine (levodopa) or dopamine antagonists (risperidone and chlorpromazine) was compared using data from the faers between 2004 and 2023, using the reporting odds ratio (ror) with relevant 95% confidence intervals (ci). |
2024-05-31 |
2024-06-02 |
Not clear |
| Hideo Kato, Chihiro Shiraishi, Mao Hagihara, Hiroshige Mikamo, Takuya Iwamot. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database. Scientific reports. vol 14. issue 1. 2024-05-31. PMID:38822123. |
no increase in incidence was associated with the concomitant use of dopamine antagonists (risperidone, ror = 1.721, 95% ci = 0.421-7.030; chlorpromazine, ror = none, 95% ci = none). |
2024-05-31 |
2024-06-02 |
Not clear |
| Samantha Alvarez-Herrera, Mauricio Rosel Vales, Gilberto Pérez-Sánchez, Enrique Becerril-Villanueva, Yvonne Flores-Medina, José Luis Maldonado-García, Ricardo Saracco-Alvarez, Raúl Escamilla, Lenin Pavó. Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia. Pharmaceuticals (Basel, Switzerland). vol 17. issue 2. 2024-02-24. PMID:38399382. |
risperidone decreases expression of serotonin receptor-2a (5-ht2a) and serotonin transporter (sert) but not dopamine receptors and dopamine transporter (dat) in pbmcs from patients with schizophrenia. |
2024-02-24 |
2024-02-26 |
Not clear |
| Sanja Strbe, Ivan Maria Smoday, Ivan Krezic, Luka Kalogjera, Vlasta Vukovic, Helena Zizek, Slaven Gojkovic, Hrvoje Vranes, Ivan Barisic, Suncana Sikiric, Marijan Tepes, Katarina Oroz, Filip Brkic, Martin Drinkovic, Lidija Beketic Oreskovic, Jelena Popic, Alenka Boban Blagaic, Anita Skrtic, Mario Staresinic, Sven Seiwerth, Predrag Sikiri. Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy. Pharmaceuticals (Basel, Switzerland). vol 16. issue 6. 2023-06-28. PMID:37375736. |
in rats with complete calvariectomy, medication (bpc 157 10 µg/kg, 10 ng/kg ip or ig) was given 5 min after distinctive dopamine agents (mg/kg ip) (haloperidol (5), fluphenazine (5), clozapine (10), risperidone (5), olanzapine (10), quetiapine (10), or aripiprazole (10), domperidone (25), amphetamine (10), and combined amphetamine and haloperidol) and assessed at 15 min thereafter. |
2023-06-28 |
2023-08-14 |
rat |
| Saleh I Alaqel, Omeima Abdullah, Adnan Alharbi, Yusuf S Althobaiti, Mansour S Alturki, Sherif Ramzy, Atiah H Almalk. Guava-fruit based synthesis of carbon quantum dots for spectrofluorometric quantitative analysis of risperidone in spiked human plasma and pharmaceutical dosage forms. RSC advances. vol 13. issue 26. 2023-06-16. PMID:37323441. |
risperidone is a selective serotonin type 2 and dopamine type 2 receptor antagonist. |
2023-06-16 |
2023-08-14 |
human |
| Zane Elfessi, Archana Jhawar, Julie Martin. Priapism Associated With the Addition of Hydroxyzine to Risperidone: A Case Report. Journal of pharmacy practice. 2023-05-05. PMID:37144572. |
risperidone is a second-generation antipsychotic that primarily blocks serotonin and dopamine receptors, while also inhibiting alpha-1 and alpha-2 receptors with high affinity. |
2023-05-05 |
2023-08-14 |
Not clear |
| Zahra Mansouri Arani, Nasrin Heidariyeh, Gholamreza Ghavipanjeh, Majid Lotfinia, Hamid Reza Banafsh. Effect of risperidone on morphine-induced conditioned place preference and dopamine receptor D2 gene expression in male rat hippocampus. Brain and behavior. 2023-04-12. PMID:37042060. |
previous studies suggest the possible effect of risperidone on brain reward system and d1 and d2 dopamine receptors' involvement in morphine-induced conditioned place preference (cpp). |
2023-04-12 |
2023-08-14 |
rat |
| Asif Ahmed Bhat, Gaurav Gupta, Obaid Afzal, Imran Kazmi, Fahad A Al-Abbasi, Abdulmalik Saleh Alfawaz Altamimi, Waleed Hassan Almalki, Sami I Alzarea, Sachin Kumar Singh, Kamal Du. Neuropharmacological effect of risperidone: From chemistry to medicine. Chemico-biological interactions. 2022-12-10. PMID:36496108. |
several lines of evidence suggest a possible role of risperidone via the antagonistic effect of dopamine d2 and 5ht-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, huntington's disease, and sleep cycle management. |
2022-12-10 |
2023-08-14 |
Not clear |
| Seth C Hopkins, Ajay Ogirala, Courtney Zeni, MaryAlice Worden, Kenneth S Kobla. Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D Clinical drug investigation. 2022-11-09. PMID:36350559. |
depicting risperidone safety profiles in clinical trials across different diagnoses using a dopamine d current methods are not designed to relate the incidence of individual adverse events reported in clinical trials to the plurality of adverse events accumulated in spontaneous reporting databases during real-world use. |
2022-11-09 |
2023-08-14 |
Not clear |
| Yoshihiro Iwamura, Tatsuo Nakayama, Atsushi Matsumoto, Yuji Ogi, Masataka Yamaguchi, Atsushi Kobayashi, Kenji Matsumoto, Yasunori Katsura, Naho Konoike, Katsuki Nakamura, Kazuhito Iked. Effect of dopamine receptor-related compounds on naive common marmosets for auditory steady state response. Journal of neurophysiology. 2022-05-18. PMID:35583977. |
subcutaneous administration of the serotonin dopamine antagonist, risperidone (0.3 mg/kg), tended to increase ip and decrease plf, but not significantly. |
2022-05-18 |
2023-08-13 |
Not clear |
| Fatima Zahra Rami, Thong Ba Nguyen, Young-Eun Oh, Maryam Karamikheirabad, Thi-Hung Le, Young-Chul Chun. Risperidone Induced DNA Methylation Changes in Dopamine Receptor and Stathmin Genes in Mice Exposed to Social Defeat Stress. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 2. 2022-04-25. PMID:35466108. |
this study investigated dna methylation and mrna expression levels of dopamine d2 and d1 receptor (drd2 and drd1, respectively), nuclear receptor subfamily 3, group c, member 1 (nr3c1) and stathmin 1 (stmn1) in brain regions of mice exposed to social defeat stress (sds) and effects of risperidone on altered methylation and mrna expression levels induced by sds. |
2022-04-25 |
2023-08-13 |
mouse |
| Samia Sultana Lira, Ishtiaque Ahamma. A comprehensive in silico investigation into the nsSNPs of Drd2 gene predicts significant functional consequences in dopamine signaling and pharmacotherapy. Scientific reports. vol 11. issue 1. 2021-12-06. PMID:34853389. |
in-depth analysis of f389v through molecular docking and dynamics simulation revealed a decline in affinity for its native agonist dopamine and an increase in affinity for the antipsychotic drug risperidone. |
2021-12-06 |
2023-08-13 |
Not clear |
| Roxana M Del Castillo, Estrella Ramos, Ana Martíne. Interaction of graphene with antipsychotic drugs: Is there any charge transfer process? Journal of computational chemistry. vol 42. issue 1. 2021-09-14. PMID:33048373. |
to have more insight into the nature of the interaction of these molecules and the differences between agonists and antagonists, we analyze the interaction of graphene with three molecules: dopamine, pramipexole (an agonist of dopamine), and risperidone (an antagonist of dopamine). |
2021-09-14 |
2023-08-13 |
Not clear |
| Roxana M Del Castillo, Estrella Ramos, Ana Martíne. Interaction of graphene with antipsychotic drugs: Is there any charge transfer process? Journal of computational chemistry. vol 42. issue 1. 2021-09-14. PMID:33048373. |
optimized structures, atomic charges, and density of states results indicate that global charges of dopamine and pramipexole are similar, while for risperidone, it is more than double. |
2021-09-14 |
2023-08-13 |
Not clear |
| Roxana M Del Castillo, Estrella Ramos, Ana Martíne. Interaction of graphene with antipsychotic drugs: Is there any charge transfer process? Journal of computational chemistry. vol 42. issue 1. 2021-09-14. PMID:33048373. |
risperidone is an antagonist, and the charge transfer process is different from dopamine. |
2021-09-14 |
2023-08-13 |
Not clear |
| Roxana M Del Castillo, Estrella Ramos, Ana Martíne. Interaction of graphene with antipsychotic drugs: Is there any charge transfer process? Journal of computational chemistry. vol 42. issue 1. 2021-09-14. PMID:33048373. |
the charge transfer is more significant with risperidone than with dopamine, and this could be related to the mechanism of action. |
2021-09-14 |
2023-08-13 |
Not clear |
| Mark E Bardgett, Tyler Downnen, Casey Crane, Emily C Baltes Thompson, Brittany Muncie, Sara A Steffen, Justin R Yates, James R Paul. Chronic risperidone administration leads to greater amphetamine-induced conditioned place preference. Neuropharmacology. vol 179. 2021-08-27. PMID:32814089. |
the density of forebrain dopamine transporters, a primary target of amphetamine, was also quantified in rats administered risperidone early in life and found to be reduced in the medial anterior, posterior, and ventral caudate nucleus. |
2021-08-27 |
2023-08-13 |
rat |
| Mark E Bardgett, Tyler Downnen, Casey Crane, Emily C Baltes Thompson, Brittany Muncie, Sara A Steffen, Justin R Yates, James R Paul. Chronic risperidone administration leads to greater amphetamine-induced conditioned place preference. Neuropharmacology. vol 179. 2021-08-27. PMID:32814089. |
these results suggest that chronic risperidone treatment modifies later locomotor activity and sensitivity to the reinforcing effects of amphetamine, perhaps via a mechanism related to decreased forebrain dopamine transporter density. |
2021-08-27 |
2023-08-13 |
rat |